Global Artificial Intelligence (AI) Partnering Terms and Agreements (2014-2020)

Dublin, May 15, 2020 (GLOBE NEWSWIRE) — The “Global Artificial Intelligence (AI) Partnering Terms and Agreements (2014-2020)” report has been added to ResearchAndMarkets.com’s offering.Trends in artificial intelligence dealmaking in the biopharma industry since 2014Analysis of artificial intelligence deal structureAccess to headline, upfront, milestone and royalty dataCase studies of real-life artificial intelligence dealsAccess to over 350 artificial intelligence dealsThe leading artificial intelligence deals by value since 2014Most active artificial intelligence dealmakers since 2014The leading artificial intelligence partnering resourcesThe report provides a detailed understanding and analysis of how and why companies enter artificial intelligence partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors artificial intelligence technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.What is actually granted by the agreement to the partner company?What exclusivity is granted?What are the precise rights granted or optioned?What is the payment structure for the deal?How are sales and payments audited?What is the deal term?How are the key terms of the agreement defined?How are IPRs handled and owned?Who is responsible for commercialization?Who is responsible for development, supply, and manufacture?How is confidentiality and publication managed?How are disputes to be resolved?Under what conditions can the deal be terminated?What happens when there is a change of ownership?What sublicensing and subcontracting provisions have been agreed?Which boilerplate clauses does the company insist upon?Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?Which jurisdiction does the company insist upon for agreement law?The initial chapters of this report provide an orientation of artificial intelligence dealmaking and business activities.Chapter 1 provides an introduction to the report.Chapter 2 provides an overview of the trends in artificial intelligence dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.Chapter 3 provides a review of the leading artificial intelligence deals since 2014. Deals are listed by headline value, signed by big pharma, most active artificial intelligence dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.Chapter 4 provides a comprehensive listing of the top 25 most active companies in artificial intelligence dealmaking with a brief summary followed by a comprehensive listing of artificial intelligence deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.Chapter 5 provides a comprehensive and detailed review of artificial intelligence partnering deals signed and announced since Jan to 2014, where a contract document is available in the public domain. The – Chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.Chapter 6 lists artificial intelligence deals by technology type.Chapter 7 provides a comprehensive and detailed review of artificial intelligence partnering deals signed and announced since Jan to 2014. The – Chapter is organized by specific artificial intelligence technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.Companies Mentioned
1ST Biotherapeutics23andMeA*STAR Bioinformatics InstituteA.I. SquaredA2A PharmaceuticalsAbramson Cancer CenterAcuraStemAdapt AnalyticsAdaptive BiotechnologiesAdentsAdventus VenturesAdynxxAetherAiforia TechnologiesAKESOgenAlberta Innovates Bio SolutionsAlberta Innovates Technology FuturesAlign TechnologyAliveCorAlliance For Clinical Trials In OncologyALS AssociationAlverno Clinical LaboratoriesAmerican Sleep Apnea AssociationAmgenAmitech SolutionsAnalytics EnginesAnthemArcherDXAres GeneticsArmARUP LaboratoriesAstraZenecaAtomwiseAtrapos TherapeuticsATUMAuransaAuron TherapeuticsAutomation AnywhereAvera HealthAXA PPP healthcareAyasdiBASFBausch & LombBayerBay LabsBCG Digital VenturesBC PlatformsBecton DickinsonBenevolentAIBenson Hill BiosystemsBergBERG AnalyticsBioBeatsBioBrightBioceptBiorelateBiozBlackfordBlackThorn TherapeuticsBlockshine TechnologyBloqcubeBody LabsBrainScopeBrigham and Women’s HospitalBristol-Myers SquibbBroad InstituteBrown UniversityBullFrog AIC4X DiscoveryCancer GeneticsCannabics PharmaceuticalsCardinal Analytx SolutionsCardiowiseCaresyntaxCarnegie Mellon UniversityCASCeaproCelgeneCellgen DiagnosticsCentogeneCentre Leon BerardCertisCharles River LaboratoriesCHDI FoundationChemi PharmaceuticalChildren’s Hospital of PhiladelphiaChildren’s National Health SystemChina Oncology FocusChristian Doppler Research AssociationCity of HopeCLEW MedicalClinical Research StrategiesClinigenClouderaCloud PharmaceuticalsCognetivity NeurosciencesCognoaCohen Veterans BioscienceColumbia UniversityConcerto HealthAIConsortium AIControl Flo MedicalCOPANCovarisCrystalGenomicsCures Within ReachCyclicaCytobankCytoReasonDacadooDana-Farber Cancer InstituteDarwinHealthDASH AnalyticsData2LifeDatavantDEARhealthDecisionQDEEP 6 AIFor more information about this report visit https://www.researchandmarkets.com/r/9f50ghResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research.CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900